43 results on '"Rutten, Caroline E."'
Search Results
2. Azathioprine/hydroxyurea preconditioning prior to nonmyeloablative matched sibling donor hematopoietic stem cell transplantation in adults with sickle cell disease: A prospective observational cohort study
3. Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study
4. Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients
5. ATG versus PTCy in matched unrelated donor haematopoietic stem cell transplantations with non‐myeloablative conditioning
6. P1536: SARS-COV-2 INFECTIONS IN PATIENTS WITH HAEMATOLOGIC MALIGNANCIES: EFFECT OF VACCINATION AND THE DEVELOPMENT OF HYBRID IMMUNITY
7. Fusariosis in patients with hematological malignancies: Two case reports
8. Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study
9. Supplementary Tables 1-3 from High-Throughput Characterization of 10 New Minor Histocompatibility Antigens by Whole Genome Association Scanning
10. Data from High-Throughput Characterization of 10 New Minor Histocompatibility Antigens by Whole Genome Association Scanning
11. Supplementary Figure 1 from High-Throughput Characterization of 10 New Minor Histocompatibility Antigens by Whole Genome Association Scanning
12. Fourth mRNA COVID-19 Vaccination in Immunocompromised Patients with Hematologic Malignancies
13. Comparison of Hidac Versus FLAG-IDA in the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Retrospective Study
14. Discordant Cellular and Humoral Responses to a 3-Dose COVID-19 mRNA Vaccination Schedule in Patients with Hematologic Malignancies
15. Sickle Cell Disease Patients Mount Adequate Humoral but Reduced Cellular Responses to COVID-19 Vaccination
16. Improved T-Cell Chimerism and Successful Withdrawal of Immunosuppression after Non-Myeloablative Stem Cell Transplantation for Sickle Cell Disease with Azathioprine/Hydroxyurea Preconditioning Added to Alemtuzumab/TBI Conditioning
17. SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies
18. Treatment of an HLH-mimic disease based on HAVCR2 variants with absent TIM-3 expression
19. Selective graft-versus-leukemia depends on magnitude and diversity of the alloreactive T cell response
20. Three-dose mRNA-1273 vaccination schedule: sufficient antibody response in majority of immunocompromised hematology patients
21. Immunogenicity of a 5‐dose pneumococcal vaccination schedule following allogeneic hematopoietic stem cell transplantation
22. T-cell subset composition and functionality in patients with Waldenström’s macroglobulinemia
23. Patient HLA-DP–Specific CD4+ T Cells from HLA-DPB1–Mismatched Donor Lymphocyte Infusion Can Induce Graft-versus-Leukemia Reactivity in the Presence or Absence of Graft-versus-Host Disease
24. Alloreactive Effector T Cells Require the Local Formation of a Proinflammatory Environment to Allow Crosstalk and High Avidity Interaction with Nonhematopoietic Tissues to Induce GVHD Reactivity
25. For Better or for Worse: COVID-19 Vaccination during or Early after (Immuno-) Chemotherapy or Hematopoietic Progenitor Cell Transplantation
26. Identification of Phosphatidylinositol 4-Kinase Type II β as HLA Class II-Restricted Target in Graft versus Leukemia Reactivity
27. HLA-DPB1 Mismatching Results in the Generation of a Full Repertoire of HLA-DPB1-Specific CD4 + T Cell Responses Showing Immunogenicity of all HLA-DPB1 Alleles
28. Allogeneic hematopoietic cell transplantation in the management of GATA2 deficiency and pulmonary alveolar proteinosis
29. Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19
30. Treatment of an HLH-mimic disease based on HAVCR2variants with absent TIM-3 expression
31. Identification of phosphatidylinositol 4-kinase type II [beta] as HLA class II-restricted target in graft versus leukemia reactivity
32. Glucose‐6‐phosphate dehydrogenase deficiency‐associated hemolysis and methemoglobinemia in a COVID‐19 patient treated with chloroquine
33. Discovery and Differential Processing of HLA Class II-Restricted Minor Histocompatibility Antigen LB-PIP4K2A-1S and Its Allelic Variant by Asparagine Endopeptidase
34. Adding Azathioprine and Hydroxyurea Preconditioning to Alemtuzumab/TBI May Improve Donor Chimerism in Matched Sibling Donor Allogeneic Stem Cell Transplantation in Adult Sickle Cell Patients
35. Risk of Severe Sars-Cov-2 Infections in COVID-19 Vaccinated Individuals with Hematologic Malignancies (SAVE HEM): A Nationwide Cohort Study in the Netherlands
36. Both permissive and nonpermissive HLA-DPB1 mismatches can induce polyclonal HLA-DPB1 specific immune responses in vivo and in vitro
37. High-Throughput Characterization of 10 New Minor Histocompatibility Antigens by Whole Genome Association Scanning
38. HLA-DPB1 Mismatching Results in the Generation of a Full Repertoire of HLA-DPB1-Specific CD4+ T Cell Responses Showing Immunogenicity of all HLA-DPB1 Alleles
39. High Throughput Minor Histocompatibility Antigen Discovery by Whole Genome Association Scanning.
40. HLA-DPB1 Mismatching Results in the Generation of a Full Repertoire of HLA-DPB1 Specific T Cell Responses Showing Immunogenicity of All HLA-DPB1 Alleles
41. Complete Remission of Immunocytoma without Graft Versus Host Disease Caused by Allo-HLA-DP Specific T Cells.
42. Patient HLA-DP–Specific CD4+ T Cells from HLA-DPB1–Mismatched Donor Lymphocyte Infusion Can Induce Graft-versus-Leukemia Reactivity in the Presence or Absence of Graft-versus-Host Disease
43. HLA-DPB1 Mismatching Results in the Generation of a Full Repertoire of HLA-DPB1-Specific CD4+ T Cell Responses Showing Immunogenicity of all HLA-DPB1 Alleles
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.